Bonus Content - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise

It sounds obvious, but still needs saying, says Ysios Capital's Karen Wagner. “How do you rise above the noise? By having the most spectacular data.” In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Wagner discussed the theme of the upcoming Bio€quity Europe conference — rising above the noise: in a sea of competition where companies vie for attention among investors and pharmas, what are the characteristics that allow them to differentiate? Wagner explains what she and her team looks for in a biotech before investing, and also discusses the role of ESG policies, including diversity, in companies. “We have absolute certainty that ESG is important."The BioCentury Show is now available as an audio podcast. The Show, featuring BioCentury one-on-one with an industry KOL, is available on Apple, Spotify and wherever you listen to your favorite podcasts and in video podcast format on BioCentury’s YouTube channel. View full story: https://www.biocentury.com/article/65229400:00 - The BioCentury Show Podcast02:12 - Spain’s Biotech Ecosystem10:06 - Investment Criteria15:03 - ESG, Diversity28:29 - AI in Drug DevelopmentReach us by sending a text